velaglucerase alfa
Alpha-derived velaglossase, which contains an amino acid sequence similar to endogenous glucosergoside, is a catalyst for the hydrolysis reaction of glucoserborozide to glucose and ceramide in lysosomes.
In patients with type 1 goiter, glucose-carbohydrate deficiency leads to the accumulation of glucocorticoids in macrophages, which causes symptoms. Alpha Valagloserase is used to reduce hepatosplenomegaly (enlarged liver and spleen) and improve anemia, thrombocytopenia, and bone disease
Mechanism of effect
In patients with Gucer type 1 disease, glucocorticosteroid deficiency leads to the accumulation of glucocorticoids in macrophages, which causes symptoms. Alpha veloglosease is used to reduce hepatosplenomegaly (enlarged liver and spleen) and improve anemia, thrombocytopenia, and bone disease.
Pharmacodynamic
In patients with type 1 goiter, glucose-carbohydrate deficiency leads to the accumulation of glucocorticoids in macrophages, which causes symptoms. Alpha valguslorazer is used to reduce hepatosplenomegaly (enlarged liver and spleen) and improve anemia, thrombocytopenia, and bone disease.
Pharmacokinetics
In patients with Gucer type 1 disease, glucocorticosteroid deficiency leads to the accumulation of glucocorticoids in macrophages, which causes symptoms. Alpha veloglosease is used to reduce hepatosplenomegaly (enlarged liver and spleen) and improve anemia, thrombocytopenia, and bone disease.
Drug indications
Gutter Disease: For Long-Term Treatment
Drug contraindications
Allergy to Alpha Valagloserase or any of its formulation components
Side effects
Side effects: Common: more than 10% Central nervous system: headache (35% -30%), dizziness (22% -8%), weakness and fatigue (less than 15%) Digestive system: Abdominal pain (19% -15%) Blood system: prolonged ptt (11% -5%, more common in children) Hypersensitivity: Hypersensitivity reaction (52% -23%) Motor nervous system: back pain (18% -17%), joint pain (15% -8% in the knee) Miscellaneous: Fever (22% -13%, more common in children) Relatively common (10% -1%) Cardiovascular system: hot flashes (more than 2%), high blood pressure (more than 2%), low blood pressure (more than 2%), increased heart rate (more than 2%) Skin: Skin rashes (more than 2%, more common in children), urticaria (more than 2%) Digestive system: nausea (10% -6%) Immune system: Increased antibody (neutralizing antibody: 2%) Motor nervous system: bone pain (more than 2%)
Interactions
Points of recommendation
Disease monitoring, CBC, liver enzymes, IgG, MRI, CT or liver and spleen ultrasound, bone density, antibody monitoring in patients with a history of increased antibodies in other alternative enzyme therapies Untouched leaves should be stored at 2 to 8. C (36 to 46. F). When the preparation is done, the product should be consumed quickly. If use is not possible immediately after preparation, the prepared and diluted product can be stored for 24 hours at 2 to 8. C (36 to 46 فار F). The infusion should be completed within 24 hours of preparation. Protect from freezing. Protect from light radiation. Discard unused solutions.Avoid infusing other supplies simultaneously
Pregnancy level
According to the available information, there is no increase in the risk of pregnancy problems after the mother's use of alpha-flagella. Pregnancy may exacerbate Goche Tib 1 disease or add new symptoms to the patient. Women with Type 1 gout have a higher risk of miscarriage if the condition is not controlled.Harmful outcomes during pregnancy may occur with medication, including enlargement of the liver and spleen (hepatosagnomegaly) and thrombocytopenia
Ask a Pharmacist